INRASTES
Selected Publications

Selected Publications

(Results: 5)
Clear all
Risitano, A.M., Mastellos, D.C., Huber-Lang, M., Yancopoulou, D., Garlanda, C., Ciceri, F. and Lambris, J.D., Complement as a target in COVID-19? Nature Reviews Immunology, Volume 20, Pages: 343-344, 2020 [doi]
Mastaglio, S., Ruggeri, A., Risitano, A.M., Angelillo, P., Yancopoulou, D., Mastellos, D.C., Huber-Lang, M., Piemontese, S., Assanelli, A., Garlanda, C., Lambris, J.D. and Ciceri, F., The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 Clinical Immunology, Volume 215, 2020 [doi]
Reis, E.S., Mastellos, D.C., Hajishengallis, G. and Lambris, J.D., New insights into the immune functions of complement Nature Reviews Immunology, Volume 19, Pages: 503-516, 2019 [doi]
Mastellos, D.C., Ricklin, D. and Lambris, J.D., Clinical promise of next-generation complement therapeutics Nature Reviews Drug Discovery, Volume 18, Pages: 707-729, 2019 [doi]
Mastellos, D.C., Blom, A.M., Connolly, E.S., Daha, M.R., Geisbrecht, B.V., Ghebrehiwet, B., Gros, P., Hajishengallis, G., Holers, V.M., Huber-Lang, M., Kinoshita, T., Mollnes, T.E., Montgomery, R.A., Morgan, B.P., Nilsson, B., Pio, R., Ricklin, D., Risitano, A.M., Taylor, R.P., Mantovani, A., Ioannidis, J.P.A. and Lambris, J.D., ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development Nature Immunology, Volume 20, Pages: 1409-1413, 2019 [doi]
INRASTES - Official Web Site
Skip to content